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Abstract 
Dopamine DRD1 receptor regulates renal function and 
vascular resistance. It plays a role in the pathogenesis of 
hypertension in animal models. In humans, the DRD1 
gene presents a A-48G polymorphism associated to 
hypertension in a Japanese population. To explore the role 
of this polymorphism on blood pressure and renal 
function in Caucasian hypertensive patients (H), we 
evaluated the allele frequencies in a populations of 697 H 
and 100 blood volunteers, and found no difference in the 
distribution of the alleles between the two groups 
(AA;AG;GG: 13%;50%;37%; and 12%; 51%;36% 
respectively). In H, we found a significant difference 
between AA and GG in serum creatinine (AA: 1.06.08 
mg/dl; GG:0.970.02 mg/dl, p<0.03). Treatment restored 
serum creatinine at levels comparable between genotypes 
(AA: 0.990.03 mg/dl; GG: 0.940.02 mg/dl, n.s.). To 
replicate the finding, in a case control study of 8 AA and 
7 GG hypertensive patients matched for age, sex and body 
mass index, in pharmacological wash out for 30 days, we 
evaluated serum (Creatinine, Na, Uric Acid, Urea) and 
urinary (volume/24h, protein/24h, creatinine 
clearance/24h) biochemistry and renal hemodynamic 
assessed by ultrasound. Once again, the AA group 
showed higher serum creatinine, Na, Uric acid and urea, 
reduced creatinine clearance and a higher level of urinary 
protein excretion. These changes occurred while no 
differences were observed in diuresis and renal vascular 
resistances. In conclusions, the DRD1 A-48G 
polymorphism identifies a class of H that is prone to 
hypertension related kidney alterations. 
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Introduction 
 
Renal dopamine receptors are important regulator of renal 




The dopamine receptors are G-protein coupled receptors 
subdivided into two families: D1-like (includes D1 and 
D5) and D2-like (includes D2, D3 and D4) grounded on 
the stimulation or inhibition of adenylyl cyclase, 
respectively
4
. D1-like receptors exist on the smooth 
muscle of renal arteries, the juxtaglomerular apparatus 
and the renal tubules. D1-like receptor agonists increase  
renal blood flow and glomerular filtration rate, as well as 
urinary excretion of sodium and water
5, 6
. Studies have 
shown that the natriuretic and diuretic response elicited by 
D1-like receptor agonist involves changes in kidney 
hemodynamic and direct tubular action
7
. At lower doses, 
the direct action on renal tubules accounts for the 
natriuresis and diuresis induced by selective D1-like 
receptor agonists
8
. Since blood pressure is affected by 
impaired sodium handling, it has been assumed that an 
aberrant renal dopaminergic system may play a role in the 
pathogenesis of some forms of hypertension
9-11
. 
In particular, renal dopamine receptor number and 
expression have been studied in animal models of 
hypertension. Watanabe et al. reported that renal cortical 
dopamine receptor density is diminished in spontaneously 
hypertensive rats compared with normotensive Wistar-
Kyoto rats at 18 weeks of age, but it was similar in both 
rats at 3 and 7 weeks of age
12
. Renal dopamine receptor 
density and expression in renal proximal tubules were 
similar in spontaneously hypertensive rats compared with 
normotensive Wistar-Kyoto rats, while renal dopamine 
receptor expression in inner medulla was decreased in 
spontaneously hypertensive rats compared with control
13, 
14
. There is defective transduction of the renal dopamine 
receptor signal in renal proximal tubules of spontaneously 
hypertensive rats, resulting in decreased inhibition of 
sodium transport by dopamine
15
. Albrecht et al reported 
that mice lacking the renal dopamine receptor gene have 
impaired regulation of renal sodium transport and 
presented elevated systolic and diastolic blood pressure
9
. 
The human dopamine receptor 1 (DRD1) gene has been 
cloned 
16
 and localized to chromosome 5 at q35.1, and its 
gene structure has been described
17
. A polymorphism, A-
48G, has been identified at -48 bp of the 5’ untranslated 
region, which correspond to the DRD1 promoter
18, 19
. This 
mutation harbor the possibility of  impaired DRD1 
expression, leading to reduced receptor density and 
signaling. Given the large potentiality of this mutation in 
the pathogenesis of high blood pressure, the frequency of 
this polymorphism has been evaluated in a Japanese 
population and shown to be highly represented among 
hypertensive patients
20
.  On the other hand,  large genome 
wide analysis have failed to confirm association of this 
gene and hypertension. when The reasons of the interest 
of this polymorphism not only resides in the pathogenesis 
of hypertension, which remains a heterogeneous and 
complex polygenic disease, but also in development of 
kidney damage related to the hypertensive states. Indeed, 
hypertension is the second cause of kidney failure, 
following diabetes. Parameters of kidney damage are used 
to adjust therapy and patients with similar levels of blood 
pressure and other anthropometric measurement, have a 
different evaluation towards organ damage, suggesting 
that the genetic background play a important role in 
determining the evolution of this condition. All the above 
considerations provided the background to verify whether 
the  DRD1 A-48G polymorphism associates to 
hypertension in a white Caucasian population. 
Furthermore we pursued exploring  the eventual 
association with  biochemical markers of kidney damage.  
Methods 
Subjects 
In order to perform an observation of the distribution of 
the DRD1 variants among hypertensive patients, we 
selected a study population of 253 essential hypertensive 
patients referring to the Hypertension Diagnosis and Care 
Outpatient Clinic of the “Federico II” University of 
Naples. Anamnesis, clinical data and biochemical features 
of the patients enrolled in this ambulatory are routinely 
stored in a computerized database that comprehends over 
25000 patients with an average follow-up of 6 years
21
. 
Patients were randomly selected among those included in 
the database. Selection criteria were the absence of 
treatment at first inclusion in the database, presence of 
essential hypertension, the absence of heart failure, 
cerebral disease, diabetes and diabetes related target organ 
damage, concomitant oncological conditions. Blood 
pressure was measured in supine, sitting and standing 
posture, according to European guidelines
22, 23
. The study 
was performed in compliance with human study 
committee regulations of the Federico II University. 
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Written informed consent was obtained from all patients. 
In another population of 14 patients, we performed a case 
control  study. Patients were selected among those 
enrolled in the observational study and were homozygous 
either for the A (AA ) or the G (GG) variant at position -
48. Patients were matched for sex, age body mass index 




Biochemical and urinal analysis 
At enrolment in the study, blood and urine samples were 
collected for determination of serum concentration of 
creatinine, uric, acid, urea, Na, K and analysis of the 
concentration of creatinine, proteins, Na, K, in the urine 
collected in 24 hours were measured by standard 
methods. Based on results, clearance of creatinine was 
calculated according to the Cockcroft-Gault formula: 
[(140-Age)*weight in kilograms/]/ serum 
creatinine*72*(sex correction factor)*BSA/1.73, where 
sex correction facto is equal 0.85 for women and 1 for 
men. 
 
Cardiac, carotid and renal arteries ultrasound 
Ultrasounds were performed using a SONOS 5500 
(Philips)  by two independent trained experienced 
physicians (NdL, MAER). Intraoperator and interassay 
variability were 5% and 6%, respectively. 
Echocardiography was performed using standard 
technique, with a dedicated ultrasound machine
25
. Cardiac 
hypertrophy was calculated based on the formula 
developed by Devereux et al.
26
; cutoffs for left ventricle 
hypertrophy were considered 110 and 130 g/m
2
 for 
females and males, respectively
27
.  
Carotid artery B-mode ultrasonography was performed 
with patients in the supine
 
position with the neck extended 
in mild rotation. The scanning protocol was performed 
with an ultrasound
 
device (Sonos 5500, Philips) equipped 
with a 7.5-MHz high-resolution
 
transducer with an axial 
resolution of 0.1 nm and examinations were recorded on 
S-VHS videotapes.
 
The maximum arterial intima-media 
thickness (IMT)
 
in up to 12 arterial walls, including the 
right and the left,
 
near and far distal common (1 cm) 
bifurcation, and proximal
 
internal carotid artery was 
estimated offline with an image
 
processing workstation.  
Subjects with a maximum IMT of >1.5 mm were 
considered to have
 
plaque according to previous studies
28
.  
Renal artery ultrasound is carried out this exam in the 
early morning after an overnight fast, with the patient 
supine position. Blood velocity is recorded at the origin of 
the renal arteries and of intralobar and arcuate vessels. 
The mean RI ([peack systolic velocity – end-diastolic 





Analysis of the DRD1 Gene Restriction Fragment 
Length Polymorphism 
From each patient we collected 15 ml of venous blood 
sample from an antecubital vein for DNA extraction. 
Genomic DNA was extracted from whole blood samples 
using a commercially available column extraction kit 
(Qiagen Midi, Chicago, Illinois, USA). A restriction 
fragment length polymorphism assay was developed to 
detect a G allele at nucleotide -48 using the following 
forward (5-GGC TTT CTG GTG CCC AAG ACA GTG-
3) and reverse (5-AGC ACA GAC CAG CGT GTT CCC 
CA-3) primers
20
. Amplification reaction was carried out 
in 25 microliters,  using 200 ng of genomic DNA, and 
TAQ DNA polymerase (Qiagen) (annealing: 63°C, 35 
cycles)  resulting  in a 405-bp fragment. The fragment 
was then digested by DdeI (New England Biolabs)  and 
resolved by electrophoresis over 3% agarose gel
20
. 
Digestion results in 3 fragments (146, 42, and 217 bp)  in 
the -48G homozygous patients, in 2 fragments (146 and 
259 bp) in the -48A homozygous patients conditions, and 




Data are presented as mean ± SD. Allele frequencies were 
calculated from the genotypes of all subjects. Significant 
differences between the total number of alleles on all 
chromosomes for the hypertensive and normotensive 
groups were assessed by 
2
 analysis. Association between 
genotype and hypertension was evaluated by multiple 
logistic linear regression analysis. Differences in the 
clinical data between the subjects with and without 
hypertension and between subjects with A/A or G/G were 
assessed by ANOVA followed by Bonferroni’s test. A p 
value < 0.05 was considered significant. 
Results 
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Demographic and genotypic data. Our population is 
largely composed of young male patients and in 75% of 
cases had a family history of hypertension (Table 1). We 
compared the variant frequencies of the DRD1 gene in 
hypertensive patients to that of 100 normotensive blood 
donors and found that they were similar between the two 
groups and in accord with those reported in other 
European populations (Table 2). 
 
Effects of DRD1 A-48G Genotype on clinical and 
biochemical characteristics.  We then stratified our 
population based on the DRD1 A-48G polymorphism. 
There was no effect of the A-48G polymorphisms on 
anthropometric, hemodynamic and cardiovascular 
ultrasound parameters (Table 3). Interestingly, patients 
bearing two copies of the A-48 allele presented with 
higher level of serum creatinine (Table 3), suggesting a 
possible interaction of the polymorphism with the kidney 
function in hypertensive patients.  
 
Effects of DRD1 genotype on kidney function and 
hemodynamics in hypertensives To further explore 
whether  DRD1 variant can differently interfere with the 
effects of high blood pressure on kidney function, we 
selected 15 patients carrying 2 copies of either the A-48 
or the G-48  DRD1 alleles. Patients were chosen to match 
for age, sex, BMI, and blood pressure, and did not present 
kidney failure or left ventricle hypertrophy. They had 
similar history of high blood pressure levels and did not 
present diabetes or dyslipidemia (Table 4). After 30 days 
of pharmacological wash out, blood pressure increased to 
a similar extent in both groups. When we looked at serum 
parameters of kidney function, we confirmed that indeed 
serum creatinine is higher in the A/A group then the G/G 
group. Furthermore, also serum Na, nitrogen and uric acid 
were higher in the A/A group, thus suggesting an effect of 
this polymorphism on kidney function (Table 5). This is 
confirmed by the analysis of the 24h urine sample. 
Indeed, despite similar volumes of urine excretion, 
calculated creatinine clearance was reduced in the DRD1 
A/A patients compared to the G/G (Table 6). Also, 
microalbuminuria was almost 10 times higher in these 
patients as compared to the G/G homozygous, indicating 
a larger kidney damage associated to the hypertensive 
state depending upon the DRD1 genotype. This 
phenotype can be related to the hemodynamic effects 
induced by the DRD1 expressed on the vasculature. We 
therefore evaluated by ultrasound the renal and kidney 
artery hemodynamics. Results are illustrated in table 7, 
and show no differences between hypertensive patients 
harboring either the A/A or the G/G variant of the DRD1 
gene. 
Discussion 
The major finding of our work is the identification of the -
48A/A variant of the DRD1 gene as a potential risk factor 
for kidney damage in hypertension. This conclusion relies 
on the evidences gathered in two different cohorts of 
patients, using two different experimental approaches. In 
the first population, using an observational design, in a 
relatively large cohort of hypertensive patients we report 
that this polymorphism has same frequency in 
hypertensive patients and a control population of 
normotensive blood donors, thus suggesting that this 
polymorphism, at least in white caucasic does not 
associate with high blood pressure. More importantly, 
though, hypertensive patients bearing two copies of the 
A-48 variant presented a significant increase in serum 
creatinine levels, which is an indicator of somewhat 
impaired kidney function. So far, hypertension related 
organ damage has been considered uniquely a 
consequence of the exposure to elevated blood pressure 
levels. Nevertheless, the observation that hypertensive 
patients with similar anthropometric parameters and blood 
pressure levels are more prone than others to develop 
hypertension related target organ damage as well the large 
familiarity for cerebrovascular events related to high 
blood pressure levels have provided the necessary 
background for the investigation of genetic determinants 
of target organ damage. We have also produced recent 
evidence that the cardiac damage related to hypertension 
is indeed determined by a naturally occurring 
polymorphism of the β2 adrenergic receptor
30
. In our 
population, similar blood pressure levels as well same 
anthropometric and clinical features across the DRD1 
genotype of our hypertensive patients were found. 
Therefore, the increase in serum creatinine could find the 
only explanation in the interference of the DRD1 
genotype with the hypertensive status, as indeed 
confirmed by the multivariate analysis. Furthermore, there 
are no differences in other parameters of hypertension 
related organ damage, namely carotid artery 
atherosclerosis and cardiac size, thus suggesting a 
specificity that can be related to the kidney abundance of 
the DRD1 gene expression.  
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To further detail the nature and characteristics of these 
kidney alterations, we decided to circumscribe the 
observation to a limited number of selected patients in 
which a deeper exploration of kidney function was 
performed. This part of the study was conducted in 
selected hypertensive patients that were chosen among the 
homozygous for the A or the G -48 variant of the DRD1 
gene, since no differences were observed between 
heterozygous and G/G homozygous patients. This case 
control study, produced evidence that the A/A population 
is more prone to kidney damage, as suggested by  larger 
microalbuminuria and reduced creatinine clearance. 
Given the distribution on both vascular smooth muscle 
cells and tubular epithelium of the DRD1 receptor within 
the kidney, the altered kidney function can be explained 
by differences in the kidney hemodynamic or the tubular 
epithelium sodium reabsorption. Our data support the 
notion that the A-48ADRD1 mutation leads to an 
impairment in the kidney filtration function since no 
differences were observed in the renal artery and 
parenchymal artery hemodynamic. 
Although our data are suggestive that the A-48 mutation 
leads to an impairment in the function of the DRD1 
receptor, the mechanism underlying this alterations are 
not known. It is possible to speculate that the mutation 
falls within a regulatory region of the promoter of the 
gene, but so far there aren’t study available in the 
literature proving this hypothesis. In this sense, our 
observation is the first to report an impairment of a 
physiological function associated with this receptor, 
therefore supporting the hypothesis that this mutation 
causes a reduced expression of the DRD1 receptor at the 
tubular level. Previous studies have explored the impact 
of this polymorphism on behavior and dependences, since 
the large abundance of this receptor in the central nervous 
system and its role in dopamine and serotonine 
metabolism
31-33
. Only another study conducted in a 
Japanese population report an association of the G/G 
variant to be more frequent among hypertensives
20
. In our 
cohort of patients we failed to observe such an 
association. The different result between the two studies 
can be well explained by ethnic differences
34
. In 
particular, among Japanese the A allele is the most 
frequent, while in our population, the G allele has a larger 
distribution. The frequency observed in our population is 
similar to that observed in other Italian and European 
populations. It is interesting to observe that this 
distribution appears to be different from that registered for 
European ancestry populations in other databases, such as 
Entrez and HAPMAP.  
In conclusion, our data support the role of the DRD1 as a 
genetic marker for hypertension related kidney damage 
and provide molecular bases for the notion that the 
hypertension related target organ damage is modified by 
genotypes. This evidence will lead to development of new 
therapeutic strategies tailored on the genetic profile of 
hypertensive patients.  
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Table 1 
Demographic, clinical and laboratory characteristics 
of the study population. Data are expressed as  mean ± 
SD or percentage of the relevant group of patients. 
SBP: Systolic Blood  Pressure;  DBP: Diastolic Bloood 
Pressure 
 n = 736 
Age (years) 56.01±11.12 
Gender (M/F %) 61.7/38.3 
Family history of  CV events (%) 
(before 55 yrs M, 65 yrs F) 
35.7 
Smokers (%) 42.5 
Ex smokers (%) 29.6 




Blood Glucose (mg/dl) 96.35±22.75 
Blood Cholesterol   (mg/dl) 209.59±39.35 
Blood Triglycerids  (mg/dl) 137.05±79.17 
HDL Cholesterol (mg/dl) 48.43±12.45 
LDL Cholesterol (mg/dl) 131.8±34.78 
Serum Creatinine (mg/dl) 0.98±0.21 
Urea ( mg/dl) 37.67±18.49 
Uricic acid (mg/dl) 5.28±2.56 
Na (mEq/l) 141.38±3.04 
K (mEq/l) 4.36±0.43 
SBP (mmHg) 159.81±22.9 
DBP (mmHg) 100.94±10.95 
HR (bpm) 75.85±26.64 
 
 
Table 2: frequencies of DRD1 -48A/G variants among 
study group and a blood donor cohort. 
 
 A/A(%) A/G(%) G/G(%) 
Hypertensives 13 50 37 
Blood Donors 12 51 36 
 
Table 3 Clinical characteristics of hypertensive 
population according to DRD1 genotype;  SBP: 
Systolic Blood  Pressure;  DBP: Diastolic Blood 
Pressure; LVED: Left Ventricle diastolic diameter; 
LVMi: Left Ventricle Mass Index; IMT: Intima Media 
Thickness 
DRD1 -48 A/A A/G G/G P 
value 
Sex (%) 28/72 39/62 36/64 n.s. 
Age (yrs) 47,9±1,3 45,7±1,1 45,6±1,4 n.s. 
BMI 26,7±0,5 26,8±0,4 27,2±0,5 n.s. 
SBP (mmHg) 142,1±2,7 142,5±1,9 144,8±2,6 n.s. 




1,06±0,08 0,95±0,02 0,97±0,02 0.023 
Urea (mg/dl) 37,3±2,0 40,3±4,0 34,0±1,3 n.s. 
Na (mEq/L) 142±0,7 141±0,4 141±0,5 n.s. 
K (mEq/L) 4,4±0,1 4,4±0,0 4,4±0,1 n.s. 




10,7±0,2 10,9±0,1 10,8±0,1 n.s. 
LVMi 113,6±3,5 119,0±1,9 116,1±2,1 n.s. 
Carotid 
IMTmax 
1,4±0,1 1,7±0,1 1,4±0,1 n.s. 
 
F=5.282, p<0.023; t=2.298, p<0.03, ANOVA 
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Age (years) 46.1±8.3 51.1±4.3 n.s. 
Sex 4 M 3F 4 M 3F n.s. 
Body mass index 24.9±2.6 28.4±3.7 n.s. 
Body Surface Area 1.8±0.2 1.9±0.2 n.s. 
SBP (mmHg) 149.6±11.4 153.4±11.4 n.s. 
DBP (mmHg) 97.8±8.1 99.2±10.7 n.s. 
Heart rate 
(bpm) 
74.6±9.9 74.3±7.2 n.s. 
Smoke (%) 14.3 14.3 n.s. 
Diabetes (%) 0 0 n.s. 
Dyslipidemia 
(%) 





6.0±5.1 6.4±4.8 n.s 
 
Table 5: Serum parameters of renal function in 









0.9±0.06 0.74±0.03 <0.05 
Na (mEq/L) 140±0.6 137±0.9 <0.05 
K
+ 
(mEq/L) 4.4±0.3 4.4±0.3 n.s. 
Uric Acid (mg/dl) 5.67±0.3 3.8±0.4 <0.05 
Urea (mg/dl) 37.7±3.1 29.4±1.2 <0.05 
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Table 6: Urinary parameters of renal function in 










1582±289 1628±398 n.s. 
Protein excretion  
(mg/24 h) 
128±85 17±16 n.s. 
Sodium excretion  
(mEq/24 h) 




49.7±9.8 58±22.1 n.s. 
Creatinine 
clearance (ml/min) 
105±6.55 133±13.9 <0.05 
 
Table 7: Hemodynamic renal parameters in hypertensives 











125.28±29.3 112.42±12.9 n.s. 
RI proximal renal 
artery 




33.5±10.99 36.48±9.01 n.s. 
RI intra-
parenchimal 
0.57±0.05 0.56±0.04 n.s. 
 
PSV (peak systolic velocity) 
RI (resistance index) 
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